Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in ctDNA-positive resected NSCLC
NCT04611776Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Jul 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: ctDNA Clearance Rate at 6 Months and Disease-Free Survival up to 159 months. Planned start Jul 2021; status: withdrawn.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04611776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611776.